Description
by
Frank S. David (Author),
Seth Robey (Author),
Andrew Matthews (Author)
If you’re a biotech executive, investor, deal maker, entrepreneur, or adviser–or aspire to be one–then you need to know how to build and analyze forecasts and valuation models of R&D-stage drugs.
THE PHARMAGELLAN GUIDE TO BIOTECH FORECASTING AND VALUATION is a comprehensive, thoroughly referenced handbook to creating and interpreting financial models for early-stage biopharma assets and companies.
– Vetted benchmarks for key drivers of income, expenses, and valuation.
– Proprietary analyses by Pharmagellan’s experienced consulting team.
– More than 150 current references from peer-reviewed research, industry white papers, and SEC filings.
Whether you’re making investment decisions, pitching to potential partners or funders, or assessing your own R&D program, this is the one-stop guide you need by your side.
Number of Pages: 138Dimensions: 0.32 x 9 x 6 INPublication Date: January 06, 2017
Reviews
There are no reviews yet.